Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

PharmaMar has announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.